Role of modelling and simulation: a European regulatory perspective
- PMID: 22257148
- DOI: 10.2165/11596650-000000000-00000
Role of modelling and simulation: a European regulatory perspective
Abstract
Modelling and simulation (M&S) of clinical data, e.g. pharmacokinetic, pharmacodynamic and clinical endpoints, is a useful approach for more efficient interpretation of collected data and for extrapolation of knowledge to the entire target population. This type of documentation is included in the majority of marketing authorization applications for new medicinal products. This article summarizes the current status of regulatory review with respect to the role of M&S in Europe from the perspective of the Swedish Medical Products Agency. At present, regulatory bodies in Europe encourage the application of the M&S approach during drug development. However, there is a lack of consensus and transparent guidance documents. The main regulatory usage is in the evaluation of dose choices in sub-populations and as support for the dosing regimen in general. The regulatory review of conestat alfa illustrates how the dose recommendation was revised during the approval procedure based on M&S information. A survey of marketing authorization applications for new medicinal products approved in 2010 revealed that the use of the information gained from M&S documentation varies with respect to both regulatory review and the applicants' presentation of the data in the submitted dossier. Increased utilization and broadened application of M&S is anticipated in pharmaceutical development, where one area of focus is medicines for paediatric patients. Accordingly, the regulatory agencies will need to increase their capability to assess and utilize this type of information, and an interactive process among regulatory agencies is warranted to provide more unified regulatory assessment and guidance. Moreover, applicants are encouraged to expand on the usage of exposure-response models to map the systemic exposure range that yields safe and efficacious treatment and to improve the presentation of the gained knowledge in summary documents of the marketing authorization applications.
Similar articles
-
The regulatory system in europe with special emphasis on allergen products.Int Arch Allergy Immunol. 2008;147(4):263-75. doi: 10.1159/000146074. Epub 2008 Jul 19. Int Arch Allergy Immunol. 2008. PMID: 18648190 Review.
-
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.Adv Exp Med Biol. 2015;871:103-30. doi: 10.1007/978-3-319-18618-4_6. Adv Exp Med Biol. 2015. PMID: 26374215 Review.
-
Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).PDA J Pharm Sci Technol. 2016 Mar-Apr;70(2):163-76. doi: 10.5731/pdajpst.2015.006171. Epub 2016 Jan 21. PDA J Pharm Sci Technol. 2016. PMID: 26797977
-
Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.J Pharm Pharm Sci. 2009;12(2):181-98. doi: 10.18433/j3fw2q. J Pharm Pharm Sci. 2009. PMID: 19732496
-
Regulatory environment for allergen-specific immunotherapy.Allergy. 2011 Jun;66(6):753-64. doi: 10.1111/j.1398-9995.2011.02552.x. Epub 2011 Feb 3. Allergy. 2011. PMID: 21288251 Review.
Cited by
-
Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.Expert Rev Clin Pharmacol. 2013 Mar;6(2):159-70. doi: 10.1586/ecp.13.6. Expert Rev Clin Pharmacol. 2013. PMID: 23473593 Free PMC article. Review.
-
Modeling and simulation in clinical pharmacology and dose finding.CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e29. doi: 10.1038/psp.2013.5. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23835940 Free PMC article.
-
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27069774 Free PMC article.
-
Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims.CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e27. doi: 10.1038/psp.2013.4. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23835938 Free PMC article. No abstract available.
-
Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.Br J Clin Pharmacol. 2014 Jul;78(1):145-57. doi: 10.1111/bcp.12322. Br J Clin Pharmacol. 2014. PMID: 24433411 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical